CCCC
NASDAQ · Biotechnology
C4 Therapeutics Inc
$4.67
+0.32 (+7.36%)
Open$4.35
Previous Close$4.35
Day High$5.17
Day Low$4.31
52W High$4.60
52W Low$1.40
Volume—
Avg Volume2.49M
Market Cap466.04M
P/E Ratio—
EPS$-1.18
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+740.3% upside
Current
$4.67
$4.67
Target
$39.24
$39.24
$29.92
$39.24 avg
$50.68
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 48.69M | 46.40M | 17.10M |
| Net Income | -142,237,907 | -121,976,289 | 3.03M |
| Profit Margin | -292.1% | -277.5% | 17.7% |
| EBITDA | -153,445,347 | -138,897,646 | 5.37M |
| Free Cash Flow | — | — | 3.54M |
| Rev Growth | +5.0% | +5.0% | +6.2% |
| Debt/Equity | — | — | 1.00 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |